China may resist US FDA visit to drug facility
15 February 2008
China may oppose a visit by the US Food and Drug Administration (FDA) to a facility producing the active ingredients for a drug linked to four deaths and hundreds of allergic reactions, the Wall Street Journal reported. The paper said a deputy director of China's State Food and Drug Administration said he did not see the need for Americans to come to China. The FDA and Baxter International, which produces the blood thinner heparin, have not released the name of the supplier. The paper named Changzhou SPL Co as one of Baxter's clients and cited a Changzhou employee as saying the firm was expecting its first visit from the FDA. Changzhou SPL is a joint venture between Wisconin-based Scientific Protein Laboratories and Changzhou Techpool Pharmaceutical Co of China.
Bookmark and Share:
- China says Baxter obstructing investigations into heparin deaths
- SFDA denies link between US deaths and Chinese-made drug
- US, China at loggerheads over heparin
- China finds contaminant in blood-thinner products
- SFDA: Importing countries must inspect drugs
subscribe to the China Economic Review.